Squadron Capital Llc Sells 10,131 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 10,131 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $23.10, for a total transaction of $234,026.10. Following the completion of the sale, the insider directly owned 6,526,633 shares of the company’s stock, valued at $150,765,222.30. This represents a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00.
• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.74, for a total transaction of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00.

OrthoPediatrics Price Performance

KIDS stock traded down $0.31 during trading on Tuesday, reaching $23.00. The company’s stock had a trading volume of 139,797 shares, compared to its average volume of 173,766. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The company’s fifty day moving average is $21.52 and its 200-day moving average is $18.72. The company has a market capitalization of $600.53 million, a P/E ratio of -13.69 and a beta of 0.98. OrthoPediatrics Corp. has a 1 year low of $14.42 and a 1 year high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. On average, research analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Several institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its holdings in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the period. Legal & General Group Plc bought a new stake in OrthoPediatrics in the second quarter worth $34,000. Northwestern Mutual Wealth Management Co. boosted its stake in OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the period. Caption Management LLC bought a new position in OrthoPediatrics during the third quarter valued at $54,000. Finally, BNP Paribas Financial Markets increased its position in OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares during the last quarter. 69.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KIDS. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. BTIG Research lifted their target price on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Finally, Needham & Company LLC lifted their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.